Introduction {#Sec1}
============

Allergic rhinitis is one of the most common allergies worldwide and one of the most common chronic disorders among children and adults \[[@CR1]\]. Early sensitization to aeroallergens and food combined with the presence of atopic dermatitis, characterized by an immunoglobulin E (IgE)-mediated inflammation, can result in the development of asthma and/or allergic rhinitis later in life in a process called "atopic march" \[[@CR2]\]. Genetic studies identified hundreds of genes associated with allergic rhinitis, and genome-wide association studies (GWASs) pinpointed single nucleotide polymorphisms (SNPs) associated with its development \[[@CR3], [@CR4]\]. However, a majority of identified SNPs lie in the non-coding genomic region, making it difficult to identify the targeted genes. Given that DNA methylation may have an impact on gene regulation \[[@CR5]\], the probability of detecting true positive associations should be improved by combining nominally significant data from genomics and epigenomics and linking them by quantitative trait loci (QTL) analysis. Methylation QTLs (mQTLs) allow assessing the impact of DNA-sequenced variations (SNPs) on DNA methylation. They have been assessed in different tissues and cell types and were shown to overlap with GWAS hits \[[@CR6]--[@CR9]\]. We used this approach to identify allergic rhinitis genes and illustrate its usefulness in the context of a complex trait.

Materials and methods {#Sec2}
=====================

Individual selection, characterization, and sample preparation {#Sec3}
--------------------------------------------------------------

We used data available from the Saguenay--Lac-Saint-Jean (SLSJ) asthma familial collection from Québec, Canada, that has data for rhinitis and allergies (Table [1](#Tab1){ref-type="table"}). This population is known for its founder effect and is more homogeneous than a cosmopolitan population \[[@CR10], [@CR11]\]. Individuals affected with rhinitis and allergies, with or without asthma, were analyzed as cases. Individuals with no rhinitis, allergies, and asthma were considered as controls. In this study, patients were defined as asthmatics based on if they either had a reported history of asthma (validated by a physician) or if at recruitment they manifested asthma-related symptoms and positive PC~20~ (\<8 mg/ml) \[[@CR12]\]. Rhinitis was self-reported, and the subject had to answer "yes" to at least one of the following questions: Have you ever had rhinitis?; Have you ever had hay fever?; and Have you ever had sneeze or rheum after contact with the following: hay, flowers, animals, and dust? Allergy was defined by a skin prick test for 26 aeroallergens (≥3 mm). All subjects were recruited and evaluated out of the pollen season \[[@CR12]\]. Recruitment and clinical evaluation of individuals as well as phenotype description can be found in Laprise \[[@CR12]\]. All subjects gave their informed consent, and the project was approved by the research ethic committee of the Centre intégré universitaire de santé et de services sociaux du SLSJ.Table 1General characterization of individuals analyzed in the studyGWAS samplesEWAS samplesControls^a^Allergic rhinitis^b^Allergic rhinitis combined with asthma^c^Controls^a^Allergic rhinitis^b^Allergic rhinitis combined with asthma^c^Number of samples187125321313048M/F ratio1:1.131:0.871:0.871:1.601:0.881:0.78Age, mean (range)^d^43 (3--85)37 (5--93)28 (5--83)29 (1--53)28 (1--59)28 (5--55)Age median^d^413826353026Smoking status, *n* (%)^e^ Non-smoker82 (44)64 (51)219 (68)14 (45)18 (60)36 (75) Ex smoker61 (33)37 (30)53 (17)8 (26)6 (20)4 (8) Smoker43 (23)21 (17)44 (14)9 (29)5 (17)7 (15)IgE, μg/L (SD)^f^202.85 (1373.66)411.27 (852.17)856.45 (2075.62)67.10 (90.45)575.40 (1380.45)597.73 (242.50)^a^Defined as not affected by either asthma, allergies, or rhinitis. ^b^Defined as being affected with both allergy and rhinitis. Allergic rhinitis phenotype is available for all samples. Allergy is defined as at least one positive response on skin prick testing (wheal diameter ≥3 mm at 10 min). Rhinitis is self-reported, and the subject had to answer "yes" to at least one of the following questions: Have you ever had rhinitis?; Have you ever had hay fever?; and Have you ever had sneeze or rheum after contact with hay, flowers, animals, and dust? Can be either combined^c^ or not^b^ with asthma. ^d^Age difference between groups were assessed using an unpaired *t* test. GWAS: controls vs allergic rhinitis *p* = 0.078 and control vs allergic rhinitis combined with asthma *p* = 1.2e−15. EWAS: controls vs allergic rhinitis *p* = 0.078 and control vs allergic rhinitis combined with asthma *p* = 0.43. ^e^Smoking status available for 186 controls, 122 allergic rhinitis, and 316 allergic rhinitis combined with asthma subjects for genome-wide association study (GWAS) samples and 31 controls, 29 allergic rhinitis, and 47 allergic rhinitis combined with asthma subjects for epigenome-wide association study (EWAS) samples. Differences between groups were assessed using a chi-square test. GWAS: controls vs allergic rhinitis *p* = 0.0045 and control vs allergic rhinitis combined with asthma *p* = 1.25e−19. EWAS: controls vs allergic rhinitis *p* = 0.049 and control vs allergic rhinitis combined with asthma *p* = 7.7e−3. ^f^Geometric mean and standard deviation (SD) for the immunoglobulin E (IgE) serum concentration calculated for 175 controls, 116 allergic rhinitis, and 302 allergic rhinitis combined with asthma subjects for GWAS samples and all subjects for EWAS samples. IgE level differences between groups were assessed using an unpaired *t* test. GWAS: controls vs allergic rhinitis *p* = 0.145 and control vs allergic rhinitis combined with asthma *p* = 2.2e−3. EWAS: controls vs allergic rhinitis *p* = 0.003 and control vs allergic rhinitis combined with asthma *p* = 0.90. Sex, age, cell count, and smoking status were used as covariates in the analyses

Genome-wide association study {#Sec4}
-----------------------------

A total of 508 subjects (321 cases and 187 controls) and 312 subjects (125 cases and 187 controls) were included in the analysis for allergic rhinitis with or without asthma, respectively. The same group of controls was used to compare to both phenotypes (i.e., allergic rhinitis and allergic rhinitis with asthma). DNA extraction, genotyping methods, and statistical analyses were described previously \[[@CR12]\]. Genotyping was performed using the Illumina 610K Quad array (Illumina, San Diego, CA, USA). Association test was performed using a quasi-likelihood score test using the MQLS program (Release 1.5, <http://www.stat.uchicago.edu/~mcpeek/software/MQLS/index.html>), which allows performing case-control association analysis using related individuals \[[@CR13]\]. The kinship coefficient was calculated using KinlnbCoef program (version 1.1, <http://www.stat.uchicago.edu/~mcpeek/software/KinInbcoef/index.html>). We included in the analysis SNPs with minor allele frequency (MAF) \>0.05, *p* value for Hardy-Weinberg equilibrium \>0.0001, and overall call rate \>95%. Samples with genotyping rate \<95% were excluded. A total of 633 samples (321 subjects with allergic rhinitis with asthma, 125 subject with allergic rhinitis only, and 187 controls (used to compare to both phenotypes)) and 506,388 SNPs were included in the analysis.

Epigenome-wide association study {#Sec5}
--------------------------------

A total of 31 controls and 48 cases for allergic rhinitis with asthma or 30 cases for allergic rhinitis alone were included in the epigenome-wide association study (EWAS) analysis. These samples are a subset of the ones used in the GWAS analysis. Unrelated subjects were included based on having allergic rhinitis with or without asthma and having no asthma, allergies, or rhinitis and based on having high or low levels of IgE. DNA extraction and sodium bisulfite conversion methods were described previously \[[@CR14]\]. The assay was carried out on the Infinium HumanMethylation450 BeadChip array (Illumina, San Diego, CA, USA). The analysis was performed using the RnBeads Bioconductor R package \[[@CR15]\]. We removed probes with at least one of the following characteristics: (1) weak signal (*p* \> 0.01) (2128 CpG sites), (2) SNP-enriched sites (4100 sites), (3) out of a CpG context (not on a CG) (3149 sites), or (4) located on sex chromosomes (11,129 sites). A total of 465,071 CpG sites were analyzed initially. Signal was then normalized, first by scaling to the internal controls using the methylumi R package \[[@CR16]\], then by applying the method of subset-quantile within array normalization (SWAN) implemented in the minfi R package \[[@CR17], [@CR18]\]. A total of 2203 sites were removed due to missing data. We removed probes that mapped multiple genomic regions (≥90% sequence similarity), that have a variant less than 10 bp from the CpG, or that have ≥2 SNPs in it. A total of 374,498 CpG sites (80.5%) were analyzed for differential DNA methylation using limma R package \[[@CR19]\]. All samples had cell counts for eosinophils, basophils, monocytes, lymphocytes, and neutrophils. The cell percentages were used as covariates as well as sex, age, smoking status, and batch effect.

Methylation quantitative trait loci analysis {#Sec6}
--------------------------------------------

To perform the mQTL analyses, we used associated SNPs (*p* \< 0.05) and CpGs (*p* \< 0.05 and Δ*β* \> 0.05) in the GWAS and EWAS for both traits. We kept associated CpGs that were located in either the gene body or 1.5-kb upstream of the transcription start site, keeping 88 and 144 CpGs for allergic rhinitis with or without asthma, respectively. SNPs were kept if present in all samples and if the three genotype groups (homozygous reference, heterozygous and homozygous alternative) were observed at least five times. A total of 529 and 625 SNPs were included in the analysis for allergic rhinitis with or without asthma, respectively. We analyzed *cis*-mQTLs where the CpG-SNP combination was less than 1 Mb apart from each other based on the distance used by the GTEX consortia for their *cis* expression quantitative trait loci (*cis-*eQTLs) (<http://www.gtexportal.org/home/documentationPage>). We used a Bonferroni correction to evaluate significance thresholds. We computed mQTLs for these SNP-CpG pairs using an additive linear model using the R package MatrixEQTL \[[@CR20]\]. Same covariates as in EWAS were included in this analysis. A total of 274 (Bonferroni *p* = 0.05/274 = 1.8e−4) and 500 (Bonferroni *p* = 0.05/500 = 1e−4) CpG-SNP comparisons were performed for allergic rhinitis with or without asthma, respectively.

Results and discussion {#Sec7}
======================

In this study, we used a novel approach that links genetic (SNPs) and functional (CpGs) data through the use of mQTLs identifying new genes associated with allergic rhinitis with or without asthma (Fig. [1](#Fig1){ref-type="fig"}). It relies on functional cellular data and reduces the stringent cutoff normally used in GWAS. Even though this is a pilot experiment with small number of samples, we identified one significant *cis-*mQTL for allergic rhinitis located in caudal-type homeobox 1 (*CDX1*) (*p* = 6.41e−5) (Table [2](#Tab2){ref-type="table"}). We also observed nine nominally associated *cis-*mQTLs located in five genes for allergic rhinitis and 16 located in nine genes for allergic rhinitis with asthma (Table [2](#Tab2){ref-type="table"}). One gene was reported being associated in both traits: ring finger protein 39 (*RNF39*). It has the highest number of mQTLs identified in both allergic rhinitis with (four) or without asthma (five).Fig. 1Flowchart presenting our approach combining genome-wide association study (GWAS) and epigenome-wide association study (EWAS) hits to identify *cis* methylation quantitative trait loci (mQTLs) that could be associated with allergic rhinitis with (ARA) or without asthma (AR). We first performed GWAS and EWAS separately for AR and ARA. We then selected marginally associated SNPs (*p* \< 0.05) where the three genotyping groups were observed at least five times. We also selected marginally associated CpGs (*p* \< 0.05) that had a Δ*β* \> 0.05 and that were located in the gene body or 1.5-kb from the transcription start site (TSS). We then linked the SNPs and CpGs that were 1 Mb apart by performing *cis-*mQTLs for both AR and ARA. We used Bonferroni *p* value cutoffs to assess significance Table 2Genes with *cis*-mQTL sites significantly associated with allergic rhinitis with or without asthmaTraitGeneLocusmQTLsGWAS analysisEWAS analysis*p* valueSNP*p* valueCpGsΔ*β* ^a^*p* valueAllergic rhinitis***CDX1*** ^***b***^chr5q32**6.41e−5**rs888989**0.0038**cg18424208−5.19**0.0002***PPAN-P2RY11*chr19p13.20.0245rs37521990.0346cg241188567.514.39e−5*RNF39* ^*c*^chr6p22.10.0090rs28448330.0270cg0556351510.110.02120.0229rs28448330.0270cg246370445.850.01320.0265rs28448330.0270cg012866857.780.02660.0411rs25238720.0123cg109303089.500.02550.0499rs25238720.0123cg012866857.780.0266*SRRT*chr7q22.10.0412rs69428240.0224cg104265815.260.0096Allergic rhinitis with asthma*ADORA1*chr1q32.10.0337rs66612840.0337cg19315653−6.260.0315*ITGB2*chr21q22.30.0381rs72752030.0381cg180120896.100.0068*LINC00336*chr6p21.310.0073rs94619240.0073cg04329454−7.160.0015*MFSD6L*chr17p13.10.0120rs98959920.0120cg116853165.010.0072*PCDH8*chr13q14.30.0152rs7327740.0295cg149508297.530.00970.0135rs37422970.0480cg149508297.530.00970.0259rs18012490.0296cg149508297.530.00970.0259rs49430460.0298cg149508297.530.0097*PITX2*chr4q250.0257rs20670040.0272cg133850165.060.02400.0249rs99927550.0289cg133850165.060.0240*RNF180*chr5q12.30.0130rs77132890.0130cg173701635.430.0021*RNF39* ^*c*^chr6p22.10.0133rs25175040.0047cg033435719.190.04510.0171rs25175040.0047cg012866858.210.04780.0401rs25352380.0248cg012866858.210.04780.0499rs25238720.0299cg012866858.210.0478*ZFPM1*chr16q24.20.0304rs7507400.0304cg049836875.530.0056^a^Δ*β* and *p* values for CpG sites and SNPs forming a *cis*-mQTL. A negative Δ*β* indicates a decrease in the percentage of methylation for cases compared to controls. All loci refer to the human hg19 reference genome^b^CDX1 is the only gene for which the mQTL *p* value survives multiple correction (*p* \< 1e-4)^c^ *RNF39* is the only gene marginally associated in both traits

The significantly or nominally associated genes were not associated with any related trait before. Interestingly, the majority of the genes linked to a SNP by the *cis*-mQTLs are not the closest ones, thus would not be the ones reported in a regular GWAS study. For example, all of the significant SNPs reported for the *RNF39 cis*-mQTLs are located 300 kb to 1 Mb away from the gene and are located closer to other genes, which were previously associated with pulmonary function (rs2844833-*HLA-F* \[[@CR21]\], rs2523872-*MUC22* \[[@CR21]\], rs2517504-*HCG22* \[[@CR21], [@CR22]\], rs2535238-*ZFP57* \[[@CR21]\]). The best example remains the one for the significantly associated mQTL that links rs888989 to a CpG located in the promoter region of the *CDX1* gene*.* The SNP is located in an intron of TNFAIP3 interacting protein 1 (*TNIP1*) and 900 kb from *CDX1*. The former was previously associated with atopic dermatitis \[[@CR23]\] and asthma \[[@CR24]\]. According to the GTEx Portal (<http://www.gtexportal.org/>), rs888989 and *CDX1* form an expression quantitative trait loci (eQTL) in the lungs (*p* = 0.04), which is not the case for *TNIP1* (*p* = 0.94). This reinforces the possible implication of this gene in allergic rhinitis and shows that our method may better assess the true genes of interest linked to the associated SNPs.

The originality of our approach resides in combining GWAS and EWAS nominally associated SNPs and CpGs, using *cis*-mQTL data, to identify genes of interest in this disease. This method has the potential to reduce false negative findings by relying on the cellular mechanisms of gene regulation compared to the use of stringent statistical corrections. The use of a well-described collection coming from a founder population and including subjects selected based on the same precise criteria allowed a more unified genetic background and phenotype. However, since this is a pilot study, the limited number of samples included in the EWAS and the GWAS may constrain the power of the findings. We were not able to test SNPs previously associated with the trait in previous GWASs because they did not meet the criteria to be included in the mQTL analysis. We also analyzed SNPs and CpGs preselected in the arrays by the manufacturers, thus excluding potentially important SNPs or CpG sites, which are not in linkage disequilibrium. DNA methylation analysis using whole blood could have limited the findings, even if correction for cell counts was included in our model. Apart from the limitations, we showed that our approach is promising and acknowledging for the lack of power in future studies will permit to better pinpoint genes of interests for different traits. Studying other tissues implicated in allergic rhinitis trait, like nasal or lung cells, could also reveal other genes implicated in the physiopathology. Genes identified in this study, notably *CDX1*, are worthwhile to be further investigated to understand the allergic rhinitis pathogenesis and the atopic march.

AR

:   Allergic rhinitis

ARA

:   Allergic rhinitis with asthma

CDX1

:   Caudal-type homeobox 1

eQTL

:   Expression quantitative trait loci

EWAS

:   Epigenome-wide association study

GWAS

:   Genome-wide association study

HCG22

:   HLA complex group 22

HLA-F

:   Major histocompatibility complex, class I, F

IgE

:   Immunoglobulin E

MAF

:   Minor allele frequency

mQTL

:   Methylation quantitative trait loci

MUC22

:   Mucin 22

RNF39

:   Ring finger protein 39

SLSJ

:   Saguenay--Lac-Saint-Jean

SNP

:   Single nucleotide polymorphism

SWAN

:   Subset-quantile within array normalization

TNIP1

:   TNFAIP3 interacting protein 1

TSS

:   Transcription start site

ZFP57

:   Zinc finger protein 57

This work was supported by Laprise and Pastinen operating grants from the Canadian Institute of Health Research (CIHR); AM was supported by the Fonds de Recherche du Québec---Santé (FRQS) doctoral training award. CL is the director of the Asthma Strategic Group of the Respiratory Health Network (RHN), investigator of CHILD Study, and is a member of the AllerGen NCE Inc. CL is the chairholder of the Canada Research Chair in the Environment and Genetics of Respiratory Disorders and Allergies, and TP is the chairholder of the Canada Research Chair in Human Genomics.

Funding {#FPar1}
=======

The study is funded by the Canadian Institute of Health research operating grant.

Availability of data and materials {#FPar2}
==================================

Data is available upon request.

Authors' contributions {#FPar3}
======================

CL collected the data and managed the SLSJ cohort and conceived and supervised the study. AM analyzed and interpreted the data and wrote the manuscript draft under the supervision of CL. CL, LPB, ML, and TP edited the manuscript. All authors reviewed and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable

Ethics approval and consent to participate {#FPar6}
==========================================

All subjects gave their informed consent, and the project was approved by the research ethic committee of the Centre intégré universitaire de santé et de services sociaux du SLSJ.
